Phase 2 study for people with Endometrial Cancer

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting

Phase Phase 2

Sponsor Canadian Cancer Trials Group

Registry number NCT05640999

Started 19 December 2022 Today 16 October 2026 Estimated completion 31 December 2028

Where this trial is running

Trial sites and the status recorded for each
Site	City	State or country	Status at this site
South Western Sydney Local Health District	Liverpool	NSW	Recruiting
Royal North Shore Hospital	St Leonards	NSW	Recruiting
Calvary Mater Newcastle Hospital	Waratah	NSW	Recruiting
Westmead Hospital	Westmead	NSW	Recruiting
Mater Research Institute South Brisbane	South Brisbane	QLD	Recruiting
Royal Darwin Hospital	Darwin	NT	Recruiting
Monash Medical Centre	Clayton	VIC	Recruiting
Frankston Hospital	Frankston	VIC	Recruiting
The Royal Women's Hospital	Parkville	VIC	Recruiting
Canberra Hospital	Garran	ACT	Recruiting
Royal Brisbane and Womens Hospital	Herston	QLD	Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over

Sex Female participants only

Healthy volunteers Not accepted

Enrolment target 393

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Patients must have had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards. There must be no macroscopic residual disease after surgery.

* Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed.

* Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2.

* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

* Patients' age must be ≥ 18 years.

* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements.

* Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language

* Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre

* Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy

Exclusion Criteria:

* Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis.

* Prior pelvic radiation.

* Patients with a history of other malignancies, except: carcinoma in-situ without evidence of invasive disease when resected, adequately treated non-melanoma skin cancer, or other tumours curatively treated with no evidence of disease for ≥ 5 years.

* Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan)

* Patients with a documented positive surgical margin.

* Patients with a documented positive peritoneal washings, if performed.

Dates on the record

Started 19 December 2022

Estimated completion 31 December 2028

Registry last updated 14 October 2026

Checked by Voxsanity 15 October 2026

Results, publications and the official record

No results are posted on the official record yet.
No publications are listed on the official record yet.
Official record and contacts on ClinicalTrials.gov – contact details for each site are kept there, and are not copied onto this page.

Sources and dates

ClinicalTrials.gov – the record this page reformats
ClinicalTrials.gov processing date: 14 October 2026.
This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.

Voxsanity

Clinical trials recruiting in Australia, from the public registries · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial, which may be relevant to my care:

Trial: NCT05640999

Sponsor: Canadian Cancer Trials Group

Phase: Phase 2

Status: Recruiting

Condition: Endometrial Cancer

More information: https://clinicaltrials.gov/study/NCT05640999

Eligibility criteria, as the registry published them

Reproduced exactly, unedited. Written for researchers rather than for patients.

Inclusion Criteria:

Patients must have had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards. There must be no macroscopic residual disease after surgery.
Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed.
Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2.
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
Patients' age must be ≥ 18 years.
Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements.
Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language
Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre
Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy

Exclusion Criteria:

Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis.
Prior pelvic radiation.
Patients with a history of other malignancies, except: carcinoma in-situ without evidence of invasive disease when resected, adequately treated non-melanoma skin cancer, or other tumours curatively treated with no evidence of disease for ≥ 5 years.
Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan)
Patients with a documented positive surgical margin.
Patients with a documented positive peritoneal washings, if performed.

A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a registered health practitioner to access unapproved therapeutic goods for individual patients.

Not medical advice. Voxsanity reformats information published by public registries. It does not give medical advice and is not a substitute for talking to your doctor.